Search Results | Cancer Discovery | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discov (2022) 12 (3): 644–653.

DOI: https://doi.org/10.1158/2159-8290.CD-21-1141

Published: 08 March 2022

View article

Includes: Supplementary data

Journal Articles

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez, Diwakar Davar, Bartosz Chmielowski, Katie M. Campbell, Riyue Bao, Heather Kelley, Aaron Morris, David Mauro, James E. Wooldridge, Jason J. Luke, George J. Weiner, Arthur M. Krieg, Mohammed M. Milhem

Cancer Discov (2021) 11 (12): 2998–3007.

DOI: https://doi.org/10.1158/2159-8290.CD-21-0425

Published: 02 December 2021

View article

Includes: Supplementary data

Journal Articles

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Darya Alizadeh, Robyn A. Wong, Sharareh Gholamin, Madeleine Maker, Maryam Aftabizadeh, Xin Yang, Joseph R. Pecoraro, John D. Jeppson, Dongrui Wang, Brenda Aguilar, Renate Starr, Claire B. Larmonier, Nicolas Larmonier, Min-Hsuan Chen, Xiwei Wu, Antoni Ribas, Behnam Badie, Stephen J. Forman, Christine E. Brown

Cancer Discov (2021) 11 (9): 2248–2265.

DOI: https://doi.org/10.1158/2159-8290.CD-20-1661

Published: 01 September 2021

View article

Includes: Supplementary data

Journal Articles

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham-Shmueli, Egmidio Medina, Galit Zelinger, Noa Shelach, Antoni Ribas

Cancer Discov (2021) 11 (9): 2158–2167.

DOI: https://doi.org/10.1158/2159-8290.CD-20-1847

Published: 01 September 2021

View article

Includes: Supplementary data

Journal Articles

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Keith T. Flaherty, James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret

Cancer Discov (2021) 11 (8): 1881–1885.

DOI: https://doi.org/10.1158/2159-8290.CD-21-0850

Published: 01 August 2021

View article

Journal Articles

Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19

Mihaela Aldea, Jean-Marie Michot, Francois-Xavier Danlos, Antoni Ribas, Jean-Charles Soria

Cancer Discov (2021) 11 (6): 1336–1344.

DOI: https://doi.org/10.1158/2159-8290.CD-21-0144

Published: 01 June 2021

View article

Journal Articles

T Cells as the Future of Cancer Therapy

Antoni Ribas

Cancer Discov (2021) 11 (4): 798–800.

DOI: https://doi.org/10.1158/2159-8290.CD-21-0022

Published: 01 April 2021

View article

Journal Articles

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Cancer Discov (2021) 11 (3): 714–735.

DOI: https://doi.org/10.1158/2159-8290.CD-20-0873

Published: 02 March 2021

View article

Includes: Supplementary data

Journal Articles

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean-Charles Soria, Gypsyamber D'Souza

Cancer Discov (2021) 11 (2): 233–236.

DOI: https://doi.org/10.1158/2159-8290.CD-20-1817

Published: 02 February 2021

View article

Includes: Supplementary data

Journal Articles

Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy

Theodore S. Nowicki, Colin Farrell, Marco Morselli, Liudmilla Rubbi, Katie M. Campbell, Mignonette H. Macabali, Beata Berent-Maoz, Begoña Comin-Anduix, Matteo Pellegrini, Antoni Ribas

Cancer Discov (2020) 10 (11): 1645–1653.

DOI: https://doi.org/10.1158/2159-8290.CD-20-0300

Published: 02 November 2020

View article

Includes: Supplementary data

Journal Articles

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Cancer Discov (2020) 10 (8): 1140–1157.

DOI: https://doi.org/10.1158/2159-8290.CD-19-1409

Published: 03 August 2020

View article

Includes: Supplementary data

Journal Articles

Trying for a BRAF Slam Dunk

Antoni Ribas, Roger S. Lo

Cancer Discov (2020) 10 (5): 640–642.

DOI: https://doi.org/10.1158/2159-8290.CD-20-0231

Published: 01 May 2020

View article

Journal Articles

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah J. Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen

Cancer Discov (2018) 8 (10): 1250–1257.

DOI: https://doi.org/10.1158/2159-8290.CD-18-0280

Published: 02 October 2018

View article

Includes: Supplementary data

Journal Articles

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Arnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix, Beata Berent-Maoz, Alistair J. Cochran, James S. Economou, Paul C. Tumeh, Cristina Puig-Saus, Antoni Ribas

Cancer Discov (2018) 8 (8): 935–943.

DOI: https://doi.org/10.1158/2159-8290.CD-17-1178

Published: 02 August 2018

View article

Includes: Supplementary data

Journal Articles

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Catherine S. Grasso, Marios Giannakis, Daniel K. Wells, Tsuyoshi Hamada, Xinmeng Jasmine Mu, Michael Quist, Jonathan A. Nowak, Reiko Nishihara, Zhi Rong Qian, Kentaro Inamura, Teppei Morikawa, Katsuhiko Nosho, Gabriel Abril-Rodriguez, Charles Connolly, Helena Escuin-Ordinas, Milan S. Geybels, William M. Grady, Li Hsu, Siwen Hu-Lieskovan, Jeroen R. Huyghe, Yeon Joo Kim, Paige Krystofinski, Mark D.M. Leiserson, Dennis J. Montoya, Brian B. Nadel, Matteo Pellegrini, Colin C. Pritchard, Cristina Puig-Saus, Elleanor H. Quist, Ben J. Raphael, Stephen J. Salipante, Daniel Sanghoon Shin, Eve Shinbrot, Brian Shirts, Sachet Shukla, Janet L. Stanford, Wei Sun, Jennifer Tsoi, Alexander Upfill-Brown, David A. Wheeler, Catherine J. Wu, Ming Yu, Syed H. Zaidi, Jesse M. Zaretsky, Stacey B. Gabriel, Eric S. Lander, Levi A. Garraway, Thomas J. Hudson, Charles S. Fuchs, Antoni Ribas, Shuji Ogino, Ulrike Peters

Cancer Discov (2018) 8 (6): 730–749.

DOI: https://doi.org/10.1158/2159-8290.CD-17-1327

Published: 31 May 2018

View article

Includes: Supplementary data

Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Cancer Discov (2018) 8 (2): 184–195.

DOI: https://doi.org/10.1158/2159-8290.CD-17-1119

Published: 04 February 2018

View article

Includes: Supplementary data

Journal Articles

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, Kimberley B. Dahlman, Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo

Cancer Discov (2017) 7 (11): 1248–1265.

DOI: https://doi.org/10.1158/2159-8290.CD-17-0401

Published: 01 November 2017

View article

Includes: Supplementary data

Journal Articles

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Cancer Discov (2017) 7 (2): 188–201.

DOI: https://doi.org/10.1158/2159-8290.CD-16-1223

Published: 05 February 2017

View article

Includes: Supplementary data

Journal Articles

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Antoni Ribas

Cancer Discov (2015) 5 (9): 915–919.

DOI: https://doi.org/10.1158/2159-8290.CD-15-0563

Published: 01 September 2015

View article

Journal Articles

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Cancer Discov (2014) 4 (4): 423–433.

DOI: https://doi.org/10.1158/2159-8290.CD-13-0440

Published: 03 April 2014

View article

Includes: Supplementary data

NARROW

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19

T Cells as the Future of Cancer Therapy

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Trying for a BRAF Slam Dunk

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only